Key Takeaways
- A quarter hit by a perfect storm: A forced plant closure and a pharma inventory correction combined to slash revenue and push the company to a net loss. Management frames FY23 as a year of consolidation, with recovery starting Q2.
- Taloja shutdown cost ₹50 crore in revenue: The MPCB closure notice halted a continuous-process plant, wiping out production that cannot be recovered. The High Court ruling allowed a restart in July, but normalization will be staggered across Q2–Q4.
- Pharma degrew 18% on channel destocking: Customers, including the largest product (~30% of pharma revenue), are working down excess inventory. Management sees this as temporary, with sales normalizing by end of Q2.
- Input cost pressure crushed margins: Raw material, solvent, and energy inflation, plus a lag in passing costs to customers, drove Pharma EBIT into negative territory and pushed the company to a PAT loss of ₹8.9 crore. Softening raw material prices offer majority relief from Q3.
- What to watch next quarter: Whether the promised step-wise revenue recovery materializes, the pace of margin improvement back to double digits, and any sign that the largest pharma product's inventory correction is truly over.
The Taloja Disruption
- Closure and restart: The MPCB issued a closure notice for the Taloja site following the Sachin GIDC incident. The Bombay High Court ruled in the company's favor, and operations resumed from early July. All plants are now fully operational.
- Financial damage: The disruption caused a revenue loss of ~₹50 crore and an EBIT impact of ~₹20 crore in Q1. Because the plant runs a continuous process across three shifts, lost production cannot be made up in a single quarter.
- Recovery path: Revenue normalization is expected in a staggered manner: Q2 better than Q1, Q3 better than Q2, with a return to regular run rate by Q3 and Q4. The Crop Protection business was the segment directly affected.
- De-risking the footprint: The company is making alternative arrangements to move products between sites, aiming to reduce the percentage contribution from any single site or building to mitigate future event risk.
Sameer Hiremath: "We're making alternative arrangements to move products around from one site to the other if and when such unfortunate events do take place in the future."
Pharma: A Demand Air Pocket
- The inventory overhang: Pharma revenue declined 18% YoY due to temporary demand softening and channel inventory correction by customers. The largest product, contributing ~30% of pharma revenue, and CDMO products were both affected.
- Normalization underway: The inventory correction is now reducing, with a positive outlook from July–August. Sales are expected to start normalizing by the end of Q2, with full benefit accruing in Q3 and Q4.
- Largest product trajectory: Management sees good long-term prospects and expects to maintain market share. Absolute growth is pegged at 5%–7%, with the product's weightage targeted to reduce from 30% to 25%–28% this year and to 20% long-term, as the portfolio diversifies.
- CDMO pipeline advancing: The company received an order for validation quantities for two intermediates for a COVID drug, and an order for an intermediate for a new chemical entity in Phase 2b clinical trials. A multi-year Animal Health project with a leading global innovator also commenced process development.
- Pharma EBIT turned negative: The segment posted an EBIT of negative ₹8 crore, driven by lower sales, a significant increase in input costs with a lag in passing them to customers, and lower absorption of fixed costs.
Crop Protection: Demand Intact, Supply Disrupted
- Revenue decline was operational, not demand-driven: Crop revenue degrew 15% YoY solely due to the Taloja disruption. The company used the downtime to undertake annual preventive maintenance at the facility. Agro operations otherwise ran at full steam.
- Demand signals are strong: Domestic demand continues to remain robust. Existing global customers are indicating a higher forecast for the next financial year, and inquiries from both existing and new customers for potential collaborations are running at 1.5x to 2x of last year's levels.
- Capacity shift opportunity: Management expects some production capacity to shift from Europe to India due to cost competitiveness, a structural tailwind the company is positioned to capture.
Vimal Kulshrestha: "Absolutely, we expect so. We expect that some of this capacity will shift to India."
Margins: Compressed Now, Recovery Promised
- Q1 margin collapse: EBITDA contracted to ₹23 crore, hit by lower sales and product mix, increased input costs for raw materials, energy and solvents, and under-absorption of fixed costs during the quarter. PAT swung to a loss of ₹8.9 crore.
- The cost pass-through problem: CDMO customers allow raw material cost pass-through, but with a 1–2 quarter lag. In the generic pharma API business, the company could not pass on cost increases because competitive market pressures kept prices flat.
- Raw material relief coming: Prices for some key raw materials and solvents have started softening. However, due to imported inventory already in transit (1–2 month pipeline), the full impact will only be felt from Q3 onwards.
- Margin recovery path: Management expects double-digit EBITDA margin from Q2 onwards, with the idea being to do better than 10%. All new projects and product selection are being done with a margin profile well in excess of 20% EBITDA, versus a historical 18%–19%.
- Long-term margin target: Using FY22 as a base, the company expects 50 to 100 basis points of year-on-year margin improvement from FY24 onwards, working out to approximately 22%–23% EBITDA margins by FY25.
Manoj Mehrotra: "In the pharma API or the own product business, unfortunately, we have not been able to pass on the cost increases because everyone has not increased the prices. So, there, we have to kind of absorb."
The Growth Bet: Capex, Capacity, and a Pipeline
- FY23 as a consolidation year: Management is explicit that FY23 is a year of consolidation to prepare for accelerated growth. Revenue is expected to be flattish versus last year (~₹1,900 crore), with the lost Q1 revenue made up over the next three quarters.
- The capex cycle is peaking: The company is completing a ₹600 crore investment cycle between last year and the end of this year. Partial benefit accrues this year, with most of the benefit from next year onwards. Full utilization of the two big capex plants will start from FY24 or FY24–25.
- Panoli multipurpose plant: Construction is on track, with commissioning expected by the end of FY23. The plant has a peak revenue potential of ~₹300 crore after three years, by FY26, though ramp-up takes time due to revalidation and approvals across multiple products.
- Revenue capacity runway: Current capacity base supports ~₹2,000 crore in revenue. Debottlenecking can add 10%–15%, and new capex benefits peak in FY25 and FY26, taking total capacity revenue potential to ~₹3,000 crore-plus.
- Growth acceleration promised: Management expects growth to accelerate into the high teens from FY24 and FY25, and aims to catch up with peers over the next five years, playing at the same level as the top two or three in each field.
Sameer Hiremath: "In the last 5 years, maybe we have not grown as fast as our competitors, but you will see, in the next 5 years, we are going to catch up and we'll be playing in the same level as the top two-three in each of our fields."
Customer & Portfolio Resilience
- No customer losses: Despite the operational disruption and demand slowdown, the company has not lost a single customer or contract in any of its businesses during the period.
- CDMO mix shift: The company is targeting CDMO to contribute 60% of revenue, up from the current 50-50 split, with margins higher than 60%. New CDMO contracts include a Phase 2b molecule for a global innovator, with commercial launch expected in the next 3–4 years.
- Pharma product engine: About 10 products are in the pipeline at various stages of development, with plans to launch three to four products in FY23. The run rate of three to four API products every year is expected to continue, though it takes two to three years for revenues to peak.
- Animal Health build-out: The company intends to complete the Animal Health plant commissioning by the end of FY23 and start validating products the following year. The multi-year contract covers ten products, with four to five worked on each year.
Anish Swadi: "I would like to reiterate that we have not lost a single customer or contract in any of our businesses during this period."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue recovery | Make up lost Q1 revenue; flattish vs FY22 (~₹1,900 crore) | FY23 (full year) |
| Quarterly revenue ramp | Q2 better than Q1, Q3 better than Q2; average of remaining three quarters above ₹500 crore | Q2–Q4 FY23 |
| Pharma sales normalization | Sales to start normalizing; full benefit from Q3 and Q4 | By end of Q2 FY23 |
| Taloja normalization | Back on regular run rate in a staggered manner | Q3 and Q4 FY23 |
| EBITDA margin recovery | Double-digit EBITDA margin from Q2 onwards | Q2 FY23 |
| Raw material cost benefit | Full impact of softening raw material prices | Q3 FY23 onwards |
| Panoli plant commissioning | Multipurpose plant at Panoli operational | End of FY23 |
| Animal Health plant commissioning | Plant complete; product validation starts following year | End of FY23 |
| Margin improvement | 50–100 bps YoY improvement on margins, using FY22 as base | FY24 onwards |
| Growth acceleration | Growth accelerating into high teens | FY24 and FY25 |
| Panoli peak revenue | ~₹300 crore peak revenue | By FY26 (3 years post-commissioning) |
| EBITDA margin target | Approximately 22%–23% EBITDA margins | By FY25 |
| CDMO revenue mix | CDMO to contribute 60% of revenue | No date (target stated) |
| Largest pharma product weightage | Reduce from 30% to 20% of pharma revenue | Long-term |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue | ₹379 cr, -17% YoY from ₹457 cr |
| EBITDA | ₹23 cr, lower due to sales decline, product mix, higher input costs, and under-absorption of fixed costs |
| PAT | Loss of ₹8.9 cr, driven by lower operating profits, higher depreciation, and marginal finance cost increase |
| Pharma division revenue | ₹224 cr, -18% YoY from ₹274 cr |
| Pharma division EBIT | Negative ₹8 cr, due to lower sales, higher input costs, lag in passing costs to customers, and lower fixed cost absorption |
| Crop Protection division revenue | ₹155 cr, -15% YoY from ₹183 cr |
| Crop Protection division EBIT | ₹10 cr, impacted by lower sales, higher raw material, solvent and energy costs, and lower fixed cost absorption |
| Taloja plant disruption impact | ₹50 cr revenue loss, ₹20 cr contribution loss in Q1 |
| Net debt | ₹680 cr as of June 30, roughly 50% term loan and 50% working capital |
| Cost of funds increase | 18 bps in Q1, with further increases expected in Q2 and Q3 |
| Long-term credit rating | A+ by ICRA, maintained |
| FY23 revenue expectation | ~₹1,900 cr, flattish vs FY22; Q2–Q4 average quarterly revenue expected above ₹500 cr |
| Panoli plant peak revenue expectation | ~₹300 cr at peak, 3 years after commissioning (FY26) |
| New project margin profile | Well in excess of 20% EBITDA, vs historical 18–19% |
| Pharma largest product concentration | ~30% of Pharma revenue, long-term target to bring down to 20% |